Cancer - Tscan Therapeutics

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05812027

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors

Condition

Head and neck cancer, cervical cancer, NSCLC, melanoma, ovarian cancer, HPV+ anogenital cancers, and other cancers with a reasonable likelihood of expressing 1 or more antigens